000282588 001__ 282588
000282588 005__ 20251209093037.0
000282588 0247_ $$2doi$$a10.1002/ana.78002
000282588 0247_ $$2pmid$$apmid:40977577
000282588 0247_ $$2ISSN$$a0364-5134
000282588 0247_ $$2ISSN$$a1531-8249
000282588 037__ $$aDZNE-2025-01348
000282588 041__ $$aEnglish
000282588 082__ $$a610
000282588 1001_ $$00009-0003-8560-4339$$aAbdelmoity, Omar$$b0
000282588 245__ $$aCross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.
000282588 260__ $$aHoboken, NJ$$bWiley-Blackwell$$c2025
000282588 3367_ $$2DRIVER$$aarticle
000282588 3367_ $$2DataCite$$aOutput Types/Journal article
000282588 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1765268790_7325
000282588 3367_ $$2BibTeX$$aARTICLE
000282588 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282588 3367_ $$00$$2EndNote$$aJournal Article
000282588 520__ $$aDirectly compare the brain glucose patterns seen with [F-18] fluorodeoxyglucose (FDG) positron emission tomography (PET) between 2 genetically determined forms of Alzheimer's disease: Down syndrome (DS) and autosomal dominant Alzheimer's disease (ADAD).Cross-sectional analyses of FDG were performed in individuals with DS (n = 76) from the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS), ADAD (n = 297), and neurotypical familial controls (n = 188) from the Dominantly Inherited Alzheimer Network (DIAN). Within-group linear regression models and generalized additive models were performed for select regional FDG uptake measures (isthmus cingulate and inferior parietal, precuneus, middle temporal gyrus, and precentral gyrus). Age, sex, apolipoprotein (APOE) ε4 carrier status, and cortical amyloid burden were included within these analyses.Even 20 years before expected onset of clinical symptoms, FDG uptake was lower for DS compared to neurotypical familial controls (p < 0.01). ADAD baseline FDG was similar to neurotypical familial controls until 7 years before expected symptom onset. Both symptomatic individuals with DS and ADAD had lower FDG compared to neurotypical familial controls (p < 0.01). A higher amyloid burden was associated with lower FDG for both genetic forms, with similar rates of decline in FDG uptake for DS and ADAD who were amyloid positive.Brain glucose metabolism is substantially lower for people with DS, even in individuals who are cognitively stable. The patterns of FDG decline are distinct in these 2 genetically determined forms of AD. The diagnostic utility of FDG-PET is specific to the genetic form of AD. ANN NEUROL 2025;98:1237-1248.
000282588 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282588 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x1
000282588 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282588 650_7 $$00Z5B2CJX4D$$2NLM Chemicals$$aFluorodeoxyglucose F18
000282588 650_7 $$2NLM Chemicals$$aRadiopharmaceuticals
000282588 650_7 $$0IY9XDZ35W2$$2NLM Chemicals$$aGlucose
000282588 650_2 $$2MeSH$$aHumans
000282588 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000282588 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000282588 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000282588 650_2 $$2MeSH$$aMale
000282588 650_2 $$2MeSH$$aFemale
000282588 650_2 $$2MeSH$$aFluorodeoxyglucose F18: metabolism
000282588 650_2 $$2MeSH$$aCross-Sectional Studies
000282588 650_2 $$2MeSH$$aDown Syndrome: diagnostic imaging
000282588 650_2 $$2MeSH$$aDown Syndrome: metabolism
000282588 650_2 $$2MeSH$$aDown Syndrome: genetics
000282588 650_2 $$2MeSH$$aPositron-Emission Tomography
000282588 650_2 $$2MeSH$$aMiddle Aged
000282588 650_2 $$2MeSH$$aAdult
000282588 650_2 $$2MeSH$$aAged
000282588 650_2 $$2MeSH$$aBrain: diagnostic imaging
000282588 650_2 $$2MeSH$$aBrain: metabolism
000282588 650_2 $$2MeSH$$aRadiopharmaceuticals
000282588 650_2 $$2MeSH$$aGlucose: metabolism
000282588 7001_ $$00000-0003-3624-2784$$aWisch, Julie K$$b1
000282588 7001_ $$aKennedy, James T$$b2
000282588 7001_ $$aGoyal, Manu$$b3
000282588 7001_ $$aVlassenko, Andrei$$b4
000282588 7001_ $$aFlores, Shaney$$b5
000282588 7001_ $$aHanden, Benjamin L$$b6
000282588 7001_ $$00000-0003-1115-6396$$aHead, Elizabeth$$b7
000282588 7001_ $$aKeator, David$$b8
000282588 7001_ $$aRafii, Michael S$$b9
000282588 7001_ $$00000-0003-2243-3547$$aLao, Patrick$$b10
000282588 7001_ $$aLai, Florence$$b11
000282588 7001_ $$aRosas, H Diana$$b12
000282588 7001_ $$aHartley, Sigan L$$b13
000282588 7001_ $$aZaman, Shahid$$b14
000282588 7001_ $$aBrickman, Adam M$$b15
000282588 7001_ $$aTudorascu, Dana$$b16
000282588 7001_ $$aLee, Joseph H$$b17
000282588 7001_ $$aAllegri, Ricardo Francisco$$b18
000282588 7001_ $$00000-0002-5943-0940$$aKeefe, Sarah$$b19
000282588 7001_ $$0P:(DE-2719)9000177$$ala Fougère, Christian$$b20
000282588 7001_ $$aLlibre-Guerra, Jorge$$b21
000282588 7001_ $$aIkeuchi, Takeshi$$b22
000282588 7001_ $$aMorris, John C$$b23
000282588 7001_ $$00000-0002-3243-0529$$aRoh, Jee Hoon$$b24
000282588 7001_ $$00000-0001-5133-5538$$aDay, Gregory S$$b25
000282588 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b26$$udzne
000282588 7001_ $$aSchofield, Peter R$$b27
000282588 7001_ $$00000-0003-2109-2955$$aGordon, Brian A$$b28
000282588 7001_ $$aBenzinger, Tammie L S$$b29
000282588 7001_ $$aAnces, Beau M$$b30
000282588 7001_ $$aSyndrome, Alzheimer's Biomarker Consortium-Down$$b31
000282588 7001_ $$aNetwork, the Dominantly Inherited Alzheimer$$b32$$eCollaboration Author
000282588 773__ $$0PERI:(DE-600)2037912-2$$a10.1002/ana.78002$$gVol. 98, no. 6, p. 1237 - 1248$$n6$$p1237 - 1248$$tAnnals of neurology$$v98$$x0364-5134$$y2025
000282588 8564_ $$uhttps://pub.dzne.de/record/282588/files/DZNE-2025-01348_Restricted.pdf
000282588 8564_ $$uhttps://pub.dzne.de/record/282588/files/DZNE-2025-01348_Restricted.pdf?subformat=pdfa$$xpdfa
000282588 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000177$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b20$$kDZNE
000282588 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b26$$kDZNE
000282588 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282588 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x1
000282588 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-18$$wger
000282588 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-18$$wger
000282588 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN NEUROL : 2022$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000282588 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bANN NEUROL : 2022$$d2024-12-18
000282588 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x0
000282588 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000282588 9201_ $$0I:(DE-2719)6000018$$kTübingen common$$lTübingen common$$x2
000282588 980__ $$ajournal
000282588 980__ $$aEDITORS
000282588 980__ $$aVDBINPRINT
000282588 980__ $$aI:(DE-2719)1111016
000282588 980__ $$aI:(DE-2719)1111015
000282588 980__ $$aI:(DE-2719)6000018
000282588 980__ $$aUNRESTRICTED